Neonc Technologies (NASDAQ:NTHI) CEO Amir Heshmatpour Acquires 15,000 Shares of Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Amir Heshmatpour purchased 15,000 shares of the company’s stock in a transaction on Monday, September 14th. The shares were bought at an average price of $3.96 per share, for a total transaction of $59,400.00. Following the completion of the transaction, the chief executive officer directly owned 3,148,000 shares in the company, valued at $12,466,080. This represents a 0.48% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Neonc Technologies Stock Down 12.4%

Shares of NASDAQ:NTHI opened at $3.31 on Wednesday. The company has a 50 day moving average of $4.04 and a 200-day moving average of $5.27. Neonc Technologies Holdings, Inc. has a twelve month low of $3.01 and a twelve month high of $12.99.

Neonc Technologies (NASDAQ:NTHI) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

Key Headlines Impacting Neonc Technologies

Here are the key news stories impacting Neonc Technologies this week:

• Positive Sentiment: Company executives continued buying shares. CEO Amir F. Heshmatpour purchased a combined 87,000 shares across transactions dated September 11, 14 and 15, while CEO Thomas C. Chen bought 10,798 shares and CFO Keithly Garnett purchased 257 shares. The purchases signal that management believes the shares may be undervalued and provide a potential confidence boost for investors. SEC insider purchase filing
• Positive Sentiment: NeOnc is advancing NEO100 toward another regulatory review, while its targeted-delivery platform and oncology programs remain central to the investment story. The company’s lead program is in Phase 2a development for glioblastoma, creating potential upside if clinical and regulatory milestones are achieved. NeOnc regulatory update
• Neutral Sentiment: Analyst opinions remain mixed. Several firms maintain Buy ratings and high price targets, but other services have issued Sell ratings; the reported consensus is Hold. These targets may be especially speculative given NeOnc’s early-stage clinical profile.
• Negative Sentiment: The company recently reported a quarterly loss of $0.58 per share, substantially worse than the consensus loss estimate of $0.12. The earnings miss reinforces concerns about cash usage and the time required to commercialize its therapies.
• Negative Sentiment: Recent financing involving healthcare-focused institutions may provide capital to advance NEO100, but issuing or selling additional shares can dilute existing shareholders. Investors are also likely cautious because NTHI remains well below its longer-term moving averages and has experienced elevated trading volume.

Institutional Investors Weigh In On Neonc Technologies

Hedge funds have recently modified their holdings of the stock. Bank of America Corp DE boosted its position in shares of Neonc Technologies by 5.0% in the 1st quarter. Bank of America Corp DE now owns 235,396 shares of the company’s stock valued at $1,650,000 after purchasing an additional 11,108 shares during the period. Westmount Partners LLC raised its holdings in Neonc Technologies by 355.2% during the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after buying an additional 153,858 shares during the period. BlackRock Inc. acquired a new stake in Neonc Technologies during the 2nd quarter worth about $815,000. Finally, Global Retirement Partners LLC acquired a new stake in Neonc Technologies during the 2nd quarter worth about $126,000.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Weiss Ratings upgraded Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 31st. BTIG Research restated a “buy” rating and issued a $15.00 price objective on shares of Neonc Technologies in a report on Tuesday, September 8th. Alliance Global Partners initiated coverage on Neonc Technologies in a research note on Tuesday, May 19th. They set a “buy” rating and a $13.00 target price for the company. Finally, Wall Street Zen lowered Neonc Technologies from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $16.00.

About Neonc Technologies

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.